CML patients exhibit many mutations occur in the BCR-ABL1 kinase domain, the most notable being T315I in the ATP-binding pocket, which renders CML patients resistant to most TKIs, lowering their prognosis and survival [12]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.